BC
ALDX icon

Boxer Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Boxer Capital’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-291,230
Closed -$1.46M – 29
2017
Q1 		$1.46M Hold
291,230
– – 0.32% 25
2016
Q4 		$1.56M Hold
291,230
– – 0.6% 20
2016
Q3 		$2.29M Hold
291,230
– – 1.02% 19
2016
Q2 		$1.66M Buy
291,230
+228,084
+361% +$1.27M 1.47% 19
2016
Q1 		$265K Hold
63,146
– – 0.26% 20
2015
Q4 		$428K Buy
+63,146
New +$424K 0.37% 14

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Boxer Capital's ALDX Position: Q2 2017 in Review

Boxer Capital sold out of Aldeyra Therapeutics (ALDX) in Q2 2017, closing a stake of 291,230 shares — an estimated $1.46M sold.

Boxer Capital first reported a position in ALDX in Q4 2015 and held it in 6 quarters. The position peaked at $2.29M in Q3 2016. 26 funds tracked by Wall St. Rank hold ALDX as of Q2 2017.

  • Boxer Capital reported no remaining Aldeyra Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Boxer Capital sold 291,230 Aldeyra Therapeutics shares in Q2 2017, an estimated $1.46M.
  • Boxer Capital first reported a position in Aldeyra Therapeutics in Q4 2015 and held it in 6 quarters.
  • Boxer Capital's Aldeyra Therapeutics position peaked at $2.29M in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2017.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.